相关实验视频

Updated: Jan 16, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

在BRCA1突变的卵巢癌中,通过自细胞激活,CDCA5倒置增强了olaparib敏感性

Wenzong Wu¹, Huan Wu², Yuqing Song³

¹Department of Clinical Medicine, Bengbu Medical University, Bengbu, 233000, Anhui, China.

Discover oncology

|September 30, 2025

概括

通过促进自和DNA损伤,CDCA5沉默与olaparib相结合可增强BRCA1突变卵巢癌的治疗. 这种组合克服了对PARP抑制剂的耐药性,改善了患者的治疗结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

发生BRCA1突变的卵巢癌预后不佳,对传统治疗有抗性.
像olaparib这样的PARP抑制剂显示出有希望的结果,但获得的耐药性仍然是一个挑战.
研究新的治疗策略对于提高治疗疗效至关重要.

研究的目的:

为了评估结合CDCA5沉默与Olaparib在BRCA1突变卵巢癌中的治疗潜力.
阐明这种组合治疗的潜在机制.
探索一种克服PARP抑制剂耐药性的新方法.

主要方法:

使用BRCA1突变卵巢癌细胞系和异种移植模型.
单独和与olaparib结合进行CDCA5敲击.
进行了功能性测定,包括CCK-8,免疫光,TEM和西斑,以评估增殖,自,DNA损伤和PI3K/AKT/mTOR信号.

主要成果:

CDCA5倒置抑制了增殖,诱导了自,并在癌细胞中引起了DNA损伤.
CDCA5淘汰和olaparib的组合协同增强了这些效应,导致显著的体内瘤生长抑制.
从机制上讲,该组合抑制了PI3K/AKT/mTOR通路,促进了自和DNA损伤,而PI3K/AKT/mTOR激活可以逆转这些损伤.

结论:

在BRCA1突变卵巢癌中,CDCA5倒置增强了olaparib的抗癌作用.
组合疗法促进了自并通过PI3K/AKT/mTOR途径加剧了DNA损伤.
这项研究提出了一种新的治疗策略,以克服PARP抑制剂耐药性并改善BRCA1突变卵巢癌的治疗结果.

关键词:

抗ARP抑制剂是一种ARP抑制剂.自自是一种自的过程.发生BRCA1突变的卵巢癌.CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 CDCA5 这就是Olaparib.在PI3K/AKT/mTOR路径中.

更多相关视频

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

相关概念视频

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

DNA Damage can Stall the Cell Cycle

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...

DNA Damage Can Stall the Cell Cycle

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...